Our findings corroborate the higher incidence of TP53 mutations among high-risk MDS, that molecular markers such as TP53 and SRSF2 mutations provide additional prognostic data to guide clinical decisions in high-risk MDS and that the use of mutation analysis during follow up may help to identify patients who are progressing before the onset of signs of progression. Here, SRSF2 is linked to myelodysplastic syndrome.